Please amend the application as follows:

In the Claims

Please amend Claims 1-16. Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - ii).

1. (Amended) A composition having neurotrophic activity, comprising a biologically active amount of at least two cytokines or functionally active derivatives or parts thereof wherein at least one of said cytokines is BMP, GDF, TGF-ß or GDNF.

2. (Amended) The composition having neurotrophic activity according to Claim 1, wherein the cytokines are selected from the group consisting of GDF, GDNF, TGF, activin A, BMP, BDNF, NGF, NT, EGF, CNTF and FGF.

3. (Amended) The composition having neurotrophic activity according to Claim 1, comprising GDF-5 and NGF.

4. (Amended) The composition having neurotrophic activity according to Claim 1, comprising GDF-5 and NT-3.

5. (Amended) The composition having neurotrophic activity according to Claim 1, comprising GDNF and TGF-β.

6. (Amended) The composition having neurotrophic activity according to Claim 1, comprising GDF-5 and GDNF.

a1

7. (Amended) The composition having neurotrophic activity according to Claim 1, comprising TGF-β and FGF-2.

8. (Amended) The composition having neurotrophic activity according to Claim 1, comprising TGF-β and CNTF.

9. (Amended) The composition having neurotrophic activity according to Claim 1, comprising TGF-β and NT-3.

10. (Amended) The composition having neurotrophic activity according to Claim 1, comprising TGF-β and NGF.

11. (Amended) The composition having neurotrophic activity according to Claim 1, comprising BMP-4 and NGF.

12. (Amended) The composition having neurotrophic activity according to Claim 1, comprising BMP-12 and NGF.

13. (Amended) The composition having neurotrophic activity according to Claim 1, comprising BMP-2 and NT-3.

14. (Amended) The composition having neurotrophic activity according to Claim 1, comprising BMP-7 and NT-3.

15. (Amended) The composition having neurotrophic activity according to Claim 1, comprising BMP-12 and NT-3.

16. (Amended) The composition having neurotrophic activity of Claim 1 further comprising a pharmaceutically acceptable carrier, diluent or any combination thereof.

Please add new Claims 17 through 56.

17. (New) A method to promote survival of neuronal cells comprising contacting neuronal cells with a composition having neurotrophic activity, said composition comprising a biologically active amount of at least two cytokines or functionally active derivatives or parts thereof wherein at least one of said cytokines is BMP, GDF, TGF-β or GDNF.

18. (New) The method according to Claim 17, wherein the cytokines contained in the composition having neurotrophic activity are selected from the group consisting of GDF, GDNF, TGF, Activin A, BMP, BDNF, NGF, NT, EGF, CNTF and FGF.

19. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises GDF-5 and NGF.

20. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises GDF-5 and NT-3.

21. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises GDNF and TGF-β.

22. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises GDF-5 and GDNF.

23. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises TGF-β and FGF-2.

24. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises TGF-β and CNTF.

25. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises TGF-β and NT-3.

26. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises TGF-β and NGF.

27. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises BMP-4 and NGF.

28. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises BMP-12 and NGF.

29. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises BMP-2 and NT-3.

30. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises BMP-7 and NT-3.

31. (New) The method according to Claim 17, wherein the composition having neurotrophic activity comprises BMP-12 and NT-3.

32. (New) A method to promote survival of neuronal cells comprising contacting neuronal cells with a composition having PI-3 kinase promoting activity.

33. (New) The method accoding to Claim 32 wherein the composition that promotes the survival of neuronal cells can be inhibited by wortmannin.

34. (New) The method according to Claim 32, wherein the composition having PI-3 kinase promoting activity comprises at least GDNF.

35. (New) A method to promote survival of neuronal cells comprising contacting neuronal cells with a composition having stabilizing activity for GPI-anchored receptors.

36. (New) The method according to Claim 35, wherein the composition having stabilizing activity for GPI-anchored receptors comprises at least TGF-β.

37. (New) The method according to Claim 35, wherein the GPI-anchored receptor is GDNFR-α.

38. (New) A method to promote survival of neuronal cells comprising contacting neuronal cells with a composition having recruiting activity for GPI-anchored receptors.

39. (New) The method according to Claim 38, wherein the composition having recruiting activity for GPI-anchored receptors comprises at least TGF-β.

40. (New) The method according to Claim 38, wherein the GPI-anchored receptor is GDNFR-α.

41. (New) A method of treating peripheral and/or central nervous system disorders using a composition having neurotrophic activity, comprising a biologically active amount of at least two cytokines or functionally active derivatives or parts thereof wherein at least one of said cytokines is BMP, GDF, TGF-β or GDNF.

42. (New) The method according to Claim 41, wherein the cytokines contained in the composition having neurotrophic activity are selected from the group consisting of GDF, GDNF, TGF, Activin A, BMP, BDNF, NGF, NT, EGF, CNTF and FGF.

43. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises GDF-5 and NGF.

44. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises GDF-5 and NT-3.

45. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises GDNF and TGF-β.

46. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises GDF-5 and GDNF.

47. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises TGF-β and FGF-2.

48. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises TGF-β and CNTF.

49. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises TGF-β and NT-3.

50. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises TGF-β and NGF.

51. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises BMP-4 and NGF.

52. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises BMP-12 and NGF.

53. (New) The method according to Claim 41, wherein the composition having neurotrophic activity comprises BMP-2 and NT-3.